Outcome of Board Meeting for Audited Results for 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bacil Pharma Ltd reported audited financial results for FY ended March 31, 2026. Total revenue was Rs 198.50 Lakhs vs Rs 123.52 Lakhs in prior year (60.7% increase), but this came entirely from other income as the company has no actual business operations. Profit after tax turned positive at Rs 155.55 Lakhs compared to a loss of Rs 6.17 Lakhs in FY25. Cash and cash equivalents dropped sharply from Rs 285.73 Lakhs to Rs 56.85 Lakhs. Borrowings increased significantly from Rs 16.39 Lakhs to Rs 1,639 Lakhs. The statutory auditor issued an unmodified (clean) opinion, but flagged that the company has no operations. The auditor noted material uncertainty about going concern as current assets (Rs 174.85 Lakhs) barely exceed current liabilities (Rs 258.04 Lakhs).
The company is essentially dormant with no operating revenue. Despite reporting a profit, the sharp cash decline and high borrowings against minimal current assets indicate serious liquidity stress. The going concern flag from auditors and management's reliance on future operations restart signals high risk for investors.